Kamada Ltd - Company Profile
Powered by 
All the sales intelligence you need on Kamada Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Kamada Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Kamada Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Kamada Pharmaceuticals (Kamada) has a portfolio of marketed products aimed at rare and serious conditions. It operates in the specialty plasma-derived sector, concentrating on diseases with limited treatment options. The company is also advancing a development pipeline that targets significant unmet medical needs. Kamada operates through two business segments: Proprietary Products and Distribution. It operates a manufacturing facility in Beit Kama, Israel, where it produces all its plasma-derived protein therapeutics.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Kamada is actively engaged in developing innovative therapies, including a plasma-derived Hyperimmune IgG Therapy for COVID-19, which is available for compassionate use in Israel. The company has partnered with Kedrion Biopharma to enhance global efforts and plans to initiate a Phase 1/2 clinical study in hospitalized COVID-19 patients, aiming to advance toward FDA acceptance of its clinical development program. In the field of Alpha-1 Antitrypsin (AAT) deficiency, Kamada is pioneering clinical research for plasma-derived proteins. The company has received acceptance from the EMA for a new Phase 3 trial design and is pursuing FDA approval for its Inhaled AAT program. This novel treatment aims to provide a user-friendly alternative to weekly intravenous infusions, enhancing patient convenience and potentially reducing healthcare costs. Kamada is also exploring early-stage development of recombinant AAT and collaborating with Massachusetts General Hospital on AAT in liquid form for organ preservation. In FY2025, the company invested US$12.9 million on its R&D activities.
Business Segments
Overview
Focuses on marketing and sales of biopharmaceuticals produced by third parties, involving product registration with the Israeli Ministry of Health (IMOH), importing, and distributing to local health maintenance organizations (HMOs), hospitals, and pharmacies. Key products include critical care pharmaceuticals delivered by injection, infusion, or inhalation, with a significant revenue contribution from plasma-derived products manufactured by European companies. Notable brands associated with the segment include Aerobika, Bramitob, Eligard, Foster, Gammaplex, Hepatect CP, Intratect, Ixiaro, Lamzede, Megalotect CP, Optivate 1000, Provocholine, Replenine - VF 1000, Ruconest, Rupafin, Varitect CP, Zenalb and Zutectra.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Includes six Food and Drug Administration (FDA)-approved plasma-derived biopharmaceutical products: Kedrab, Cytogam, Varizig, Winrho SDF, Hepgam B, Glassia, Kamrab, Kamrho (D), and two equine-based anti-snake venom products. These products are marketed in over 30 countries and manufactured at the company’s cGMP-compliant, FDA-approved facility in Beit Kama, Israel, using proprietary technology for protein and IgG extraction from human plasma, as well as at third-party contract manufacturers. - Kedrab, a human rabies immune globulin, is distributed in the US through a strategic agreement with Kedrion. - Cytogam, indicated for CMV disease prophylaxis, is sold in the US and Canada. - Varizig is used for post-exposure prophylaxis of Varicella in high-risk individuals. - Winrho SDF is indicated for the treatment of immune thrombocytopenic purpura (ITP) and for suppressing rhesus isoimmunization (RH). - Hepagam B helps prevent the recurrence of Hepatitis B in liver transplant recipients and provides post-exposure prophylaxis. - Glassia is used for intravenous AAT deficiency treatment. - Kamrho (D) is for hemolytic disease prophylaxis and treatment of immune thrombocytopenic purpura. - Echis coloratus and Vipera palaestinae antiserums are used for treating snake bites.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer